Acute Myeloid Leukemia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Acute Myeloid Leukemia Pipeline Drugs Market Overview
Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute nonlymphocytic leukemia, is a fast-growing form of cancer of the blood and bone marrow. It is characterized by clonal expansion of immature “blast cells” in the peripheral blood and bone marrow, resulting in ineffective erythropoiesis and bone marrow failure. Most often, AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells. The most common risk factor for AML is myelodysplastic syndrome, followed by myelofibrosis and aplastic anemia. AML is a highly heterogeneous, hematologic malignancy in terms of clinical features, underlying pathogenesis, and treatment outcomes with a variable prognosis.
The acute myeloid leukemia marketed and pipeline drugs assessment report provides a data-driven overview of the current and future competitive landscape in acute myeloid leukemia therapeutics.
Acute Myeloid Leukemia Marketed and Pipeline Drugs Market Overview by Mechanism of Action
The major mechanism of action segments in the acute myeloid leukemia marketed and pipeline drugs market are enzyme inhibitor, genes, nucleic acids, and related components inhibitor, receptor agonist, protein and peptide inhibitor, ligand depletor, receptor inhibitor, receptor antagonist, and cytotoxic to cell.
Acute Myeloid Leukemia Marketed and Pipeline Drugs Market Analysis by Mechanism of Action
For more mechanism of action insights, download a free report sample
Acute Myeloid Leukemia Marketed and Pipeline Drugs Market Overview by Route of Administration
The major routes of administration segments in the acute myeloid leukemia marketed and pipeline drugs market are injection, oral therapies, and topical therapies.
Acute Myeloid Leukemia Marketed and Pipeline Drugs Market Analysis by Route of Administration
For more route of administration insights, download a free report sample
Market Report Scope
Mechanism of Action | Enzyme Inhibitor, Genes, Nucleic Acids, and Related Components Inhibitor, Receptor Agonist, Protein and Peptide Inhibitor, Ligand Depletor, Receptor Inhibitor, Receptor Antagonist, and Cytotoxic to Cell |
Route of Administration | Injection, Oral Therapies, and Topical Therapies |
Scope
GlobalData’s Acute Myeloid Leukemia: Competitive Landscape in 2022 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type and Route of Administration
- Product Profiles with Sales Forecast
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Acute Myeloid Leukemia market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Acute Myeloid Leukemia market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the major mechanisms of action in the acute myeloid leukemia marketed and pipeline drugs assessment market?
The major mechanism of action segments in the acute myeloid leukemia marketed and pipeline drugs market are enzyme inhibitor, genes, nucleic acids, and related components inhibitor, receptor agonist, protein and peptide inhibitor, ligand depletor, receptor inhibitor, receptor antagonist, and cytotoxic to cell.
-
What are the major routes of administration in the acute myeloid leukemia marketed and pipeline drugs assessment market?
The major route of administration segments in the acute myeloid leukemia marketed and pipeline drugs market are injection, oral therapies, and topical therapies.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.